Market Overview:
The global cytokine market size reached USD 89.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach USD 163.3 Billion by 2032, exhibiting a growth rate (CAGR) of 6.76% during 2024-2032.
Report Attribute
|
Key Statistics
|
Base Year
|
2023
|
Forecast Years
|
2024-2032
|
Historical Years
|
2018-2023
|
Market Size in 2023 |
USD 89.6 Billion |
Market Forecast in 2032 |
USD 163.3 Billion |
Market Growth Rate (2024-2032) |
6.76% |
A cytokine refers to a group of proteins, peptides, or glycoproteins released by specific cells to control the growth and activity of the immune system and blood cells. It can regulate immunity, inflammation, and hematopoiesis on account of its high-affinity picomolar concentrations. It is usually injected under the skin or into muscles or veins to help prevent or manage chemotherapy side effects and treat cancer. It also boosts anti-cancer activities by sending signals that make abnormal cells die and normal cells live longer. Presently, it is gaining widespread adoption in cell and gene therapy for the expansion and differentiation of various cell types, ex vivo cultures, and other therapeutic approaches.
Cytokine Market Trends:
The coronavirus disease (COVID-19) is transmitted via droplets that can induce the excessive production of proinflammatory cytokines and lead to acute respiratory distress syndrome (ARDS) aggravation and tissue damage. As tissue damage can result in multi-organ failure and death, there is a rise in the demand for solutions that target cytokines to manage patients, improve survival rates, and reduce mortality. Apart from this, the increasing prevalence of cancer, in confluence with the escalating demand for minimally invasive surgeries (MIS) that provide less post-operative pain and complications and faster recovery time, is contributing to the market growth. Moreover, as cytokines act as diagnostic, prognostic, and therapeutic agents and biomarkers for health and diseases, they are gaining traction in diverse functions, including immune cell differentiation, inflammation, angiogenesis, tumorigenesis, neurobiology, and viral pathogenesis. Besides this, the rising cases of atopic dermatitis (AD), a recurrent, chronic, and inflammatory skin disease that processes with severe itchiness, is driving the demand for new cytokines in the pathogenesis of AD and developing improved therapeutic targets.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global cytokine market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on cytokine type, therapeutic application and end user.
Breakup by Cytokine Type:
- Tumor Necrosis Factor-TNF
- Interleukins-Il
- Interferons-IFN
- Epidermal Growth Factor-EGF
- Others
Breakup by Therapeutic Application:
- Cancer
- Asthma and Airway Inflammation
- Arthritis
- Others
Breakup by End User:
- Pharmaceutical and Biotechnology Companies
- Contract Research Organizations
- Academic and Research Institutes
Breakup by Region:
- North America
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Middle East and Africa
Competitive Landscape:
The report has also provided a comprehensive analysis of the competitive landscape in the global cytokine market. Detailed profiles of all major companies have also been provided. Some of the companies covered include:
- AbbVie Inc.
- Abcam plc
- Amgen Inc.
- Applied Biological Materials Inc. (abm)
- Bio-Techne Corporation
- F. Hoffmann-La Roche AG
- GenScript Biotech Corporation
- Randox Laboratories Ltd.
- Thermo Fisher Scientific Inc.
- UCB S.A.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Report Coverage:
Report Features |
Details |
Base Year of the Analysis |
2023 |
Historical Period |
2018-2023 |
Forecast Period |
2024-2032 |
Units |
Billion USD |
Segment Coverage |
Cytokine Type, Therapeutic Application, End User, Region |
Region Covered |
Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered |
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered |
AbbVie Inc., Abcam plc, Amgen Inc., Applied Biological Materials Inc. (abm), Bio-Techne Corporation, F. Hoffmann-La Roche AG, GenScript Biotech Corporation, Randox Laboratories Ltd., Thermo Fisher Scientific Inc. and UCB S.A. |
Customization Scope |
10% Free Customization |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Questions Answered in This Report:
- How has the global cytokine market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global cytokine market?
- What are the key regional markets?
- What is the breakup of the market based on the cytokine type?
- What is the breakup of the market based on the therapeutic application?
- What is the breakup of the market based on the end user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global cytokine market and who are the key players?
- What is the degree of competition in the industry?